Board summary
Key figures
48,318
Registered population
60.0% aged 18–64
20.8%
Aged 65+
ICB 19.0% · England 17.9%
7.4%
Ethnic minority (non-White)
3.1% Asian · England 9.6%
18.6%
In IMD quintile 1
ICB 31.9% · England 21.0%
~8,128
Core20 residents (est.)
Resident basis; registered basis ~9,017 · see page 3
8,232
Hypertension register
+6.44% in 3 yrs · England +5.60%
469
SMI register
11.8% of Cheshire East (LAD)'s
1,058
COPD register
Reviews +6.81% in 3 yrs
Forecast to 2030
9,792
Hypertension patients, 2030
+1,560 on today
69.5%
QRISK ≥20% on statins, 2030
+3.75pp over 3 yrs
5.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension and frail diabetes control trail England.
Hypertension BP control is 62.9% (England 70.3%), including 58.8% under 80, while frail diabetes HbA1c control is 73.8% (England 81.9%), which may reflect titration.
Respiratory reviews and SMI checks lag benchmarks.
Asthma reviews reach 57.8% of 2,904 patients (about 1,200 unreviewed; England 65.7%), while SMI BP (72.8%) and alcohol checks (68.8%) also trail England.
Population, age and ethnicity
Patients aged 65+ make up 20.8% of the list, above England at 17.9%
Across 48,318 registered patients, 20.8% (10,040 patients) are aged 65+, trailing Cheshire East (LAD) at 22.6% but above NHS Cheshire and Merseyside Integrated Care Board at 19.0% and England at 17.9%. Working-age adults aged 18–64 make up 60.0% (28,992 patients). Ethnicity figures reflect Census usual residents rather than registered patients: 92.6% are White (Cheshire East (LAD) 94.4%, NHS Cheshire and Merseyside Integrated Care Board 93.0%, England 81.1%), with a 7.4% ethnic minority population. This older demographic may increase frailty care demands, which proactive clinical reviews could test.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire East LA) | 2,129 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 73.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.9% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire East LA) | 939 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire East LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 18.6% overall but spans 37.4 pp between practices
The Core20 cohort is 18.6% across CREWE - GHR PCN, above Cheshire East (LAD) (9.2%) but below NHS Cheshire and Merseyside Integrated Care Board (31.9%) and England (21.0%). Deprivation spans 37.4 pp across practices: Grosvenor Medical Centre has a 39.3% Core20 share (6,207 estimated patients), Hungerford Medical Centre has 22.6% (2,398 estimated patients), and Rope Green Medical Centre has 1.9% (412 estimated patients). Resident Core20 counts estimate 8,128 people across national IMD deciles 1 and 2.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
469
SMI register
0.99% recorded prevalence
240
Learning disability register
0.51% recorded prevalence
21
Care homes, 918 beds
In the PCN catchment
8.8%
Provide unpaid care
Cheshire East (LAD), Census 2021
Recorded learning disability prevalence is 0.5% (240 patients, England 0.6%) and severe mental illness is 1.0% (469 patients, England 1.0%). Catchment capacity includes 21 care homes with 918 beds, though bed capacity does not establish registered patient occupancy. Crude recorded prevalence does not establish unmet need, so sustaining annual health reviews across both registers remains the primary operational focus.
Severe mental illness: physical health checks
On the 1.0% SMI register, BP checks reach 72.8% (England 83.4%), BMI checks 69.7% (England 82.1%), and alcohol recording 68.8% (England 81.8%). Lower completion across individual checks may reflect outreach gaps to test by recall audit.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,232
Hypertension register
+6.44%
Register growth, 3 yrs
Cheshire East (LAD) +6.54% · England +5.60%
+4.33pp
BP control, under 80
≤140/90 · +2.02pp aged 80+
+1,560
More patients by 2030
Forecast 9,792 (19.72%)
Hypertension case-finding and control
Hypertension prevalence is 17.4% (8,232 patients), above England (15.2%), Cheshire East (LAD) (17.3%) and NHS Cheshire and Merseyside Integrated Care Board (16.8%), though implied denominators deviate from the 48,318 list. Recent blood pressure checks reach 83.7% (England 90.0%). Blood pressure control trails comparators: 58.8% of patients aged under 80 meet target (England 67.8%, Cheshire East (LAD) 66.6%, ICB 66.4%), and 73.7% aged 80 and over meet threshold (England 81.2%). Across practices, under-80 control is 56.2% at Rope Green Medical Centre, 58.6% at Hungerford Medical Centre, and 62.8% at Grosvenor Medical Centre. Lower blood pressure control rates across the register indicate that clinical review and treatment escalation warrant PCN-wide prioritisation.
Lipids and statins
Adult lipid-regulating prescribing is 1,975 rate per 1,000 (England 4,100 rate, Cheshire East (LAD) 2,422 rate). Statin uptake is 67.1% in diabetes aged 40+ without CVD (England 73.2%) and 61.2% for QRISK ≥ 20% (England 63.6%). Lower primary prevention coverage against England suggests an opportunity to audit high-risk cohorts and expand statin initiation.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 77,101 | £1.90 | £1.71 | £1.86 | £146,492 |
| Cardiovascular (all), 2025 | 106,493 | £4.78 | £4.37 | £3.33 | £509,037 |
In 2026, the PCN prescribed 77,101 lipid-regulating items at £1.90 per item (spend £146,492), compared with £1.86 in England, £1.72 in Cheshire East (LAD) and £1.71 in the ICB. The PCN spent £3,084 more than at England's unit cost. Unit cost is an expenditure indicator rather than an efficiency measure, and differences may reflect product choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+10.24%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−4.65%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.2% (1,058 patients), above Cheshire East (1.8%) and England (1.9%), yet the COPD review rate of 72.3% trails England (76.4%). Asthma prevalence is 6.5% (2,904 patients), but annual reviews reach only 57.8%, lagging Cheshire East (64.5%) and England (65.7%), leaving about 1,200 unreviewed patients (calculated 1,225). Prescribing for ages 5-19 is 2,033 rate per 1,000 (England 1,488 rate). Lower review rates amid elevated prescribing may indicate missed opportunities for routine disease control.
Cancer register and children's immunisation
Cancer register prevalence is 4.4% (2,061 patients), above England (3.8%) and below Cheshire East (LAD) (4.9%). In childhood immunisation, age-5 MMR dose 2 is 93.4%, below the 95.0% target by 1.6 pp, and 4-in-1 booster coverage is 91.7%, below the 95.0% target by 3.3 pp, despite exceeding England (82.8% and 80.9%). A 4.1 pp difference from MMR dose 1 (97.5%) highlights pre-school drop-off to address via recall.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of staged cancers across NHS Cheshire and Merseyside ICB (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) and 19.5 pp below the 75.0% ambition. Known-stage coverage was 72.8% (13,490 of 18,522). This ICB context frames PCN screening reach: cervical screening among women aged 25 to 49 is 68.3%, trailing Cheshire East (73.6%) and varying from 60.2% at Grosvenor Medical Centre and 65.3% at Hungerford Medical Centre to 76.8% at Rope Green Medical Centre. Screening shortfalls at Grosvenor Medical Centre and Hungerford Medical Centre highlight priorities for targeted uptake initiatives.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Mid Cheshire Hospitals NHS Foundation Trust achieved 80.0% on the 28-day faster diagnosis standard (exceeding the 75.0% standard; ICB 77.2%, England 79.3%), while East Cheshire NHS Trust reached 81.1% and University Hospitals of North Midlands NHS Trust reached 80.6%. However, Mid Cheshire fell below the 31-day standard at 86.2% (standard 96.0%; ICB 95.7%, England 92.5%) and below the 62-day standard at 71.1% (standard 85.0%; ICB 76.2%, England 71.2%). Diagnostic 6+ week waits at Mid Cheshire were 12.7% overall (England 23.1%), though colonoscopy waits reached 30.3%.
| Pathways within standard (%) | Mid Cheshire | of North Midlands | East Cheshire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 79.95 | 80.65 | 81.08 | 77.25 | 79.32 |
| 31-day treatment (96%) | 86.21 | 93.85 | 96.30 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 71.12 | 68.84 | 53.41 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mid Cheshire | of North Midlands | East Cheshire | England |
|---|---|---|---|---|
| MRI | 5.15 | 36.13 | 26.62 | 21.40 |
| CT | 1.09 | 2.86 | 11.49 | 9.92 |
| Echocardiography | 5.51 | 45.39 | 26.24 | 28.48 |
| Colonoscopy | 30.34 | 46.53 | 10.85 | 30.83 |
| Gastroscopy | 31.89 | 15.49 | 10.25 | 29.02 |
| All 15 DM01 tests | 12.72 | 22.94 | 16.17 | 23.14 |
| Community services activity | Cheshire East residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 72,825 | 541,280 |
| Referrals | 18,280 | 97,150 |
| Patients with a contact | 21,910 | 146,240 |
Community services (residents of Cheshire East), Jun 2026 (provisional). In June 2026, Cheshire East recorded 135,460 community care activities and 72,825 contacts (provisional experimental data), within an ICB total of 1,332,205 activities. Adults aged 65 and over accounted for 60.8% of borough contacts (44,295 contacts). These figures reflect wider local authority activity rather than PCN provision, showing substantial community workload supporting older patients.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF overall achievement ranged from 91.7% at Rope Green Medical Centre to 98.5% at Grosvenor Medical Centre (England 92.5%). Vaccination and immunisation achievement diverged by 26.1 pp, from 70.2% at Rope Green Medical Centre to 96.4% at Hungerford Medical Centre. Personalised care adjustments ranged from 8.2% at Rope Green Medical Centre to 13.7% at Grosvenor Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Rope Green | 115 | 1.9 | 39.8% | 78.7% | 87.1% |
| Grosvenor | 122 | 39.3 | 37.3% | 69.0% | 68.4% |
| Hungerford | 110 | 22.6 | 36.5% | 71.2% | 57.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Smoking support fell 6.7 pp whereas heart failure reviews rose +23.3%
Over three years (2023 to 2025), clinical process trends diverged. The widest lags were in psychosis alcohol recording, which fell 2.9 pp (England +5.4 pp) to 68.8% (England 81.8%), and smoking cessation advice, which fell 6.7 pp (England +0.1 pp) to 92.2% (England 94.2%). In contrast, heart failure reviews grew +23.3% (England +8.7%) to 77.0%, severe mental illness blood pressure checks rose +11.3 pp (England +4.4 pp), and asthma reviews rose +10.2% (England +4.4%). These divergences could reflect uneven recall workflows between chronic disease and mental health registers, which clinical audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Alcohol record (psychosis)
Smoking support (SMI)
Asthma register
Breast screening (53-70)
Cancer register
Heart failure reviews
BP check (SMI)
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire East (LAD) | Asset | PCN | Cheshire East (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 21 (918 beds) | n/a | Schools (catchment) | 86 | n/a |
| Children's centres | 3 | 14 | Places of worship | 45 | 272 |
| Libraries | 1 | 16 | Day centres (VCS) | n/a | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 9 | 41 | Primary academies | 17 | 78 |
| Special schools | 2 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension and diabetes control recall
On the 8,232 hypertension register (17.4%), BP control is 62.9% (England 70.3%; under-80s 58.8% vs 67.8%). Frail diabetes HbA1c control is 73.8% (England 81.9%) and statins 67.1% (England 73.2%). For discussion: establish pharmacist-led recall and medicine titration clinics for uncontrolled hypertension, frail diabetes and statin initiation. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Asthma and COPD annual review recall
Asthma annual reviews reach 57.8% across 2,904 patients (Cheshire East (LAD) 64.5%, ICB 62.3%, England 65.7%), leaving 1,225 (about 1,200) unreviewed; COPD reviews reach 72.3% (England 76.4%). For discussion: run single-template asthma and COPD recall with after-school and flexible slots, reviewing inhaler prescribing alongside annual checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Combined SMI physical health check outreach
Across the 469-patient SMI register (1.0%), BP checks are 72.8% (England 83.4%), BMI recording is 69.7% (England 82.1%) and alcohol recording is 68.8% (England 81.8%, fell 2.9 pp vs England +5.4 pp). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Proactive older adult frailty reviews (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension BP review protocol (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool immunisation recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Hypertension and diabetes control recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Asthma and COPD annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 3 · Combined SMI physical health check outreach (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
